MacroGenics shares rise 21.61% intraday after reporting strong 2025 financial results and key 2026 product milestones.

Macrogenics surged 21.61% intraday, driven by the company reporting stronger-than-expected 2025 financial results (revenue of $149.5 million exceeding forecasts by $13.38 million, and GAAP losses of $1.18 per share outperforming expectations), a $189.9 million cash balance extending its runway through 2027, and key 2026 product pipeline milestones including IND submissions and Phase 1 data disclosures for MGC030, MGC026, and MGC028.